Upon joining the study, you will be randomly assigned to receive either the study medication, elritercept, or a placebo. A placebo is a substance that looks like the medication but does not contain the active ingredient.

The study is designed to be double-blind, meaning neither you nor the study team will know which treatment you are receiving. This helps ensure the results are not influenced by expectations.

If you are assigned to receive elritercept, it will be administered as a solution for injection under the skin, known as subcutaneous use.

The dosage, frequency, and duration of administration will be determined by the study protocol, and you will be informed of these details by the study team.

Throughout the study, you will undergo regular assessments to monitor your health and the effects of the treatment. This includes blood tests, vital signs checks, and possibly electrocardiograms (ECGs) to measure heart activity.

The primary goal is to evaluate if elritercept can reduce the need for red blood cell transfusions in participants with myelodysplastic syndromes (MDS).

The study will assess whether you achieve transfusion independence for at least 8 weeks from the start of the study through week 24. Transfusion independence means you do not require red blood cell transfusions during this period.

Secondary outcomes include achieving transfusion independence for 24 weeks and monitoring any side effects or adverse events that may occur during the study.

The study is expected to continue until 2032, but your participation will be for a specific duration as outlined by the study team.

Upon completion, you will receive information about the treatment you received and any relevant findings from the study.